Claims for Patent: 5,817,656

Summary for Patent: 5,817,656

Title:	Mental disorders
Abstract:	2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of mental disorders. The compound has the following structure: ##STR1##
Inventor(s):	Beasley, Jr.; Charles M. (Indianapolis, IN), Chakrabarti; Jiban Kumar (Frimley, GB2), Hotten; Terrence Michael (Hants, GB2), Tupper; David Edward (Reading, GB2)
Assignee:	Eli Lilly and Company (Indianapolis, IN) Eli Lilly and Company Limited (Basingstoke, GB2)
Application Number:	08/748,293
Patent Claims:	1. A method of treating a patient suffering from or susceptible to a pathologic psychological condition selected from the group consisting of Unspecified Mental Retardation; Attention-Deficit Hyperactivity Disorder; Conduct Disorder, Undifferentiated Type; Chronic Motor or Vocal Tic Disorder; Transient Tic Disorder; Tic Disorder NOS; Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Depression; Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, Uncomplicated; Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Depression; Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, Uncomplicated; Bipolar Disorder, Mixed, Severe, without Psychotic Features; Bipolar Disorder, Manic, Severe, without Psychotic Features; Bipolar Disorder, Depressed, Severe, without Psychotic Features; Major Depression, Single Episode, Severe, without Psychotic Features; Major Depression, Recurrent, Severe, without Psychotic Features; Multi-infarct Dementia, with Depression; Multi-Infarct Dementia, Uncomplicated; Senile Dementia NOS; Presenile Dementia NOS; Dementia; Organic Mood Disorder; Organic Personality Disorder; Organic Mental Disorder; Body Dysmorphic Disorder; Hypochondriasis; Somatization Disorder; Undifferentiated Somatoform Disorder; Somatoform Disorder NOS; Intermittent Explosive Disorder; Kleptomania; Pathological Gambling; Pyromania; Trichotillomania; and Impulse-Control Disorder NOS; comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the condition. 2. A method of claim 1 wherein the condition is Unspecified Mental Retardation; Attention-Deficit Hyperactivity Disorder; Conduct Disorder, Undifferentiated Type; Organic Mood Disorder; Organic Personality Disorder; Organic Mental Disorder; Chronic Motor or Vocal Tic Disorder; Transient Tic Disorder; or Tic Disorder NOS. 3. A method of claim 1 wherein the condition is Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Depression; Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Depression; Multi- infarct Dementia, with Depression; Senile Dementia NOS; Presenile Dementia NOS; or Dementia. 4. A method of claim 1 wherein the condition is Bipolar Disorder, Mixed, Severe, without Psychotic Features; Bipolar Disorder, Manic, Severe, without Psychotic Features; Bipolar Disorder, Depressed, Severe, without Psychotic Features; Major Depression, Single Episode, Severe, without Psychotic Features; or Major Depression, Recurrent, Severe, without Psychotic Features. 5. A method of claim 1 wherein the condition is Body Dysmorphic Disorder; Hypochondriasis; Somatization Disorder; Undifferentiated Somatoform Disorder; Somatoform Disorder NOS; Intermittent Explosive Disorder; Kleptomania; Pathological Gambling; Pyromania; Trichotillomania; or Impulse-Control Disorder NOS. 6. A method of claim 1 wherein the effective amount is from 1 to 20 mg per day. 7. A method of treating a patient suffering from or susceptible to a pathologic psychological condition selected from the group consisting of Mental Retardation, Severity Unspecified; Attention-Deficit/Hyperactivity Disorder; Disruptive Behavior Disorder NOS; Chronic Motor or Vocal Tic Disorder; Transient Tic Disorder; Tic Disorder NOS; Dementia of the Alzheimer's Type, With Late Onset, With Depressed Mood; Dementia of the Alzheimer's Type, With Late Onset, Uncomplicated; Dementia of the Alzheimer's Type, With Early Onset, With Depressed Mood; Dementia of the Alzheimer's Type, With Early Onset, Uncomplicated; Bipolar I Disorder, Most Recent Episode Mixed, Severe Without Psychotic Features; Bipolar I Disorder, Most Recent Episode Manic, Severe Without Psychotic Features; Bipolar I Disorder, Most Recent Episode Depressed, Severe Without Psychotic Features; Major Depressive Disorder, Single Episode, Severe Without Psychotic Features; Major Depressive Disorder, Recurrent, Severe Without Psychotic Features; Vascular Dementia, With Depressed Mood; Vascular Dementia, Uncomplicated; Dementia Due to a Medical Condition; Mood Disorder Due to a Medical Condition; Personality Change Due to a Medical Condition; Dementia NOS; Body Dysmorphic Disorder; Hypochondriasis; Somatization Disorder; Undifferentiated Somatoform Disorder; Somatoform Disorder NOS; Intermittent Explosive Disorder; Kleptomania; Pathological Gambling; Pyromania; Trichotillomania; and Impulse-Control Disorder NOS; comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the condition. 8. A method of claim 7 wherein the effective amount is from 1 to 20 mg per day. 9. A method of treating a patient suffering from or susceptible to the pathologic psychological condition called Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Delirium, comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the condition. 10. The method of claim 9 wherein the effective amount is from 1 to 20 mg per day. 11. A method of treating a patient suffering from or susceptible to the pathologic psychological condition called Personality Disorder, Schizoid, comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the condition. 12. A method of treating a patient suffering from or susceptible to the pathologic psychological condition called Personality Disorder, Schizotypal, comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid additional salt thereof, that is effective to treat the condition.